The clinical research department of a large pharmaceutical company has developed an experimental drug that would prevent infection from all types of COVID-19 variants in human bodies. They are now seeking approval from Health Canada to proceed with further testing. One of the Health Canada standards requires that the proportion of individuals who are administered a drug and experienced secondary effects be less than 5%. The results from the company's phase 1 testing are presented in the following table. Unvaccinated Vaccinated Secondary effects 30 20 No secondary effects 617 633 Consider these data as the sample data. The company is preparing the documentation to support their request for approval from Health Canada. Based on the combined results for their unvaccinated and vaccinated groups, they want to perform a statistical test to demonstrate that they meet the required "less than 5%" standard for secondary effects using a 10% significance level. Answer the following questions. Question 16 (1 point) Let p denote the proportion of individuals who were administered the drug in the company phase 1 study (unvaccinated and vaccinated groups combined) and experienced secondary effects. The correct hypotheses for the test are: The critical value for the test is: 1.282 -1.645 -1.282 1.645 Question 20 (1 point) The decision and conclusion for this test are: test statistic critical value, thus Ho cannot be rejected. There is insufficient evidence to qualify for the "less than 5%" standard. test statistic > critical value, thus Ho can be rejected. There is sufficient evidence to qualify for the "less than 5%" standard. The clinical research department of a large pharmaceutical company has developed an experimental drug that would prevent infection from all types of COVID-19 variants in human bodies. They are now seeking approval from Health Canada to proceed with further testing. One of the Health Canada standards requires that the proportion of individuals who are administered a drug and experienced secondary effects be less than 5%. The results from the company's phase 1 testing are presented in the following table. Unvaccinated Vaccinated Secondary effects 30 20 No secondary effects 617 633 Consider these data as the sample data. The company is preparing the documentation to support their request for approval from Health Canada. Based on the combined results for their unvaccinated and vaccinated groups, they want to perform a statistical test to demonstrate that they meet the required "less than 5%" standard for secondary effects using a 10% significance level. Answer the following questions. Question 16 (1 point) Let p denote the proportion of individuals who were administered the drug in the company phase 1 study (unvaccinated and vaccinated groups combined) and experienced secondary effects. The correct hypotheses for the test are: The critical value for the test is: 1.282 -1.645 -1.282 1.645 Question 20 (1 point) The decision and conclusion for this test are: test statistic critical value, thus Ho cannot be rejected. There is insufficient evidence to qualify for the "less than 5%" standard. test statistic > critical value, thus Ho can be rejected. There is sufficient evidence to qualify for the "less than 5%" standard
